-month period ended 30 June 2020 and 2019, consolidated financial statement has net profit of Baht 4 million and Baht 48 million, respectively. This was resulted from the effect of the outbreak of

of 2020. The Company (iiG) and ICE/iiXP (the subsidiaries), recorded the total Assets of 443.14 Mb.and 480.68 Mb respectively. The current assets presented in the audited financial statement consist of

per share (Baht) 0.08 - 100.0% Remark : EBITDA = Profit before finance costs, income tax, Depreciation and Amortization Statement of Income : Million Baht ZIGA INNOVATION PUBLIC COMPANY LIMITED 999

Siwarapornskul Funding Source: Internal working capital of the Company Share Transfer Date: 31 March 2020 Hence, according to the Company’s latest consolidated financial statement ended 31 December 2019, the total

) (1.50) 14.76% 438.69 474.69 (35.99) -8.20% เพิ่ม (ลด) TOTAL ASSETS TOTAL LIABILITIES TOTAL SHAREHOLDERS' EQUITY Statement of Financial Position For Quarter 1 Year 2020 (Million Baht) 5 | MANAGEMENT

02-634-0135 www.interpharma.co.th 4. MP Financial Statement Balance Sheet (Unit : Baht) 2017 Audited Statement 2018 Audited Statement 2019 Audited Statement Assets Current Assets Cash and cash

with the same period of last year. The income statement in brief is presented as following: DOD BIOTECH PUBLIC COMPANY LIMITED เลขที ่111 หมู่ที ่2 ต ำบลท่ำจีน อ ำเภอเมืองสมุทรสำคร จังหวดัสมุทรสำคร 74000

results, as follows. Statement of comprehensive income Revenue from hospital operations The Company booked revenue from hospital operations amounted to Baht 612.74 million and Baht 573.69 million for the

results, as follows. Statement of comprehensive income Revenue from hospital operations The Company booked revenue from hospital operations amounted to Baht 370.32 million and Baht 612.74 million for the

would like to explain and analyze the operating results that have changed for Quarter 3 Ending 30 November 2019 with the following details: Unit : million baht Statement of financial position for the 3